Form 4: Axogen Director Alan M. Levine Reports Acquisition of Shares and Stock Options

Alan M. Levine, a director of Axogen, Inc., reported the acquisition of common stock and stock options related to his service on the board.

Summary

• On June 6, 2024, Alan M. Levine, a director of Axogen, Inc., reported a transaction involving the acquisition of 10,653 shares of common stock.
• Following the transaction, Levine directly owns 28,912 shares of Axogen, Inc.
• Levine also acquired 18,248 employee stock options with an exercise price of $7.04, exercisable from June 6, 2024, and expiring on June 6, 2034.
• These options represent the right to purchase 18,248 shares of common stock.
• The stock options and restricted stock units were granted as part of his annual equity grant for service as a Director on the Axogen, Inc. Board of Directors.
• The equity grant is valued at $150,000 as of the grant date and vests on June 6, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of shares and options, which is neither overtly positive nor negative.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grant suggests an ongoing commitment to aligning director incentives with shareholder value.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of shares and options by a director is a common occurrence.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates